Clinuvel Pharmaceuticals Limited (AU:CUV) has released an update.
Clinuvel Pharmaceuticals Limited has reported a strong financial performance for the fiscal year ending June 30, 2024, with a 13% increase in revenues to A$88.2 million and an impressive 16% rise in net profits to A$35.6 million. The company also announced a fully franked final dividend of $0.05 per share, underscoring its commitment to shareholder returns. These results reflect the company’s growth and operational success during the period.
For further insights into AU:CUV stock, check out TipRanks’ Stock Analysis page.
